Sanofi Pasteur Inc.

Immunovaccine Technologies Inc.

Ludwig Institute for Cancer Research Limited

Horizon Technology Finance Corporation

Neil L Berinstein

Laszlo Radvanyi

Corey Lovitt

Scott Gallichan

Devender Singh-Sandhu

Artur Pedyczak

Mark Parrington

James Tartaglia

Raymond P Oomen

Shi-Xian Cao

Marc Mansour

Genevieve Mary Weir

Marianne Michelle Stanford

Philippe Moingeon

Thierry R Boon-Falleur

Dennis L Panicali

Linda R Gritz

John A Tine

Pierre Vander Bruggen

Brian Barber

Devender Satsangi Singh Sandhu

The present invention provides methods for improving the efficacy of a vaccine in the treatment of cancer. The methods of the invention comprise the administration of at least two doses of an agent that interferes with DNA replication prior to vaccination with a survivin vaccine. Also provided are compositions for use in the methods of the invention.

Method for improving the efficacy of a survivin vaccine in the treatment of cancer

The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.

Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer

The present invention relates to peptides, polypeptides, and nucleic acids and the use of the peptide, polypeptide or nucleic acid in preventing and/or treating cancer. In particular, the invention relates to peptides and nucleic acid sequences encoding such peptides for use in diagnosing, treating, or preventing melanoma.

Multi-antigen vectors of melanoma

The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.

Monoclonal antibodies and uses thereof

Tumor antigens for prevention and/or treatment of cancer

The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. 

Tumor antigens Bfa5 for prevention and/or treatment of cancer

An improved method of inducing and/or enhancing an immune response to a tumor antigen is disclosed. The method involves administering the tumor antigen, nucleic acid coding therefor, vectors and/or cells comprising said nucleic acid, or vaccines comprising the aforementioned to a lymphatic site.

Method of inducing and/or enhancing an immune response to tumor antigens

The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.

Immunogenic polypeptides encoded by MAGE minigenes and uses thereof

Growing community of inventors

Toronto, Canada

Neil L Berinstein